Statistik Asas
| CIK | 895464 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Yubo International Biotech Limited
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 13, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21320 YUBO INTERNATIONAL |
|
| July 25, 2025 |
EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 23, 2025, between Yubo International Biotech Limited, a New York corporation (the “Company”), and the purchasers identified on the signature pages hereto (including their successors and assigns, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreem |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 23, 2025 Date of Report (Date of earliest event reported) YUBO INTERNATIONAL BIOTECH LIMITED (Exact name of Registrant as Specified in Charter) New York 000-21320 11-3074326 (State or Other Jurisdiction of (Commission (IRS Emplo |
|
| May 14, 2025 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21320 YUBO INTERNATIONAL |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☐ Confidential, of the Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☒ Definitive Information Statement YUBO INTERNATIONAL BIOT |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, of the Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ☐ Definitive Information Statement YUBO INTERNATIONAL BIOT |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21320 YUBO INTERNATIO |
|
| March 31, 2025 |
EXHIBIT 19.1 YUBO INTERNATIONAL BIOTECH LIMITED INSIDER TRADING POLICY PURPOSE It is illegal for any employee, contractor, officer or director of Yubo International Biotech Limited or its subsidiaries (the “Company”) to trade in the securities of the Company while in the possession of material nonpublic information about the Company. For that reason, there are some rules you’ll need to know and fo |
|
| March 31, 2025 |
EXHIBIT 10.1 |
|
| March 31, 2025 |
EXHIBIT 21.1 List of Subsidiaries of Yubo International Biotech Limited Legal Name of the Subsidiary Jurisdiction Platinum International Biotech Co., Ltd. Cayman Islands Platinum International Biotech (Hong Kong) Limited Hong Kong Yubo International Biotech (Chengdu) Limited China Yubo Global Biotechnology (Chengdu) Co., Ltd. China |
|
| March 31, 2025 |
Letter from Michael T. Studer CPA P.C. EXHIBIT 16.1 March 31, 2025 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We were previously principal accountant for Yubo International Biotech Limited, a New York corporation (the “Company”). We have read the disclosures under “Item 9. Changes in and Disagreement with Accountants on Accounting and Financial Disclosure” in the Company’s Annu |
|
| March 31, 2025 |
Sublease agreement, dated April 20, 2024 [English Translation] EXHIBIT 10.3 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Sublease Agreement Party A: Shenzhen Supplies Group Co., Ltd. Authorized representative: [***] Unified social credit code: [***] Party B: Xinanji Medical Technology (Shenzhen) Co., Ltd. Legal representative: [***] Unified social credit code: [***] Party C: Li Huang Valid ID numbe |
|
| March 31, 2025 |
Lease Agreement, dated April 1, 2024 [English Translation] EXHIBIT 10.2 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Housing Lease Contract Lessor ( Party A ) : Shenzhen Materials Group Co., Ltd. Legal representative: Wu Yuesheng Address: [***] Zip Code: [***] Contact number: [***] Unified social credit code: [***] Authorized agent: [***] ID number: [***] Lessee ( Party B ) : EpiAis Biomedical |
|
| January 10, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 Yubo International Biotech Limited (Exact name of registrant as specified in its charter) New York 000-21320 11-3074326 (State or other jurisdict |
|
| January 6, 2025 |
Letter from Michael T. Studer CPA P.C. EXHIBIT 16.1 January 6, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We were previously principal accountant for Yubo International Biotech Limited, a New York corporation (the “Company”). We have read the disclosures under “Item 4.01. Changes in Registrant’s Certifying Accountant” in the Company’s current report on Form 8-K, dated Januar |
|
| January 6, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2024 Yubo International Biotech Limited (Exact name of registrant as specified in its charter) New York 000-21320 11-3074326 (State or other jurisdiction of incorporation |
|
| November 13, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21320 YUBO INTERNATI |
|
| August 19, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21320 YUBO INTERNATIONAL |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transitio |
|
| July 11, 2024 |
July 11, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street, N.E. Washington, D.C. 20549 Attn: Jeanne Baker Terence O’Brien Robert Augustin Jane Park Re: Yubo International Biotech Limited Annual Report on Form 10-K for the Year Ended December 31, 2023 Filed April 12, 2024 Response filed June 7, 2024 F |
|
| June 7, 2024 |
June 7, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street, N.E. Washington, D.C. 20549 Attn: Jeanne Baker Terence O’Brien Robert Augustin Jane Park Re: Yubo International Biotech Limited Annual Report on Form 10-K for the Year Ended December 31, 2023 Filed April 12, 2024 File No. 000-21320 Ladies and |
|
| May 20, 2024 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21320 YUBO INTERNATIONAL |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| April 12, 2024 |
Employment Agreement of Yang Wang [English translation] EXHIBIT 10.2 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Employment Contract Party A: Yubo International Biotech (Beijing) Limited Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31 Xishiku Street, Xicheng District, Beijing Party B: Yang Wang ID Card No.: [***] Tel: [***] Address: [***] In accordance with the |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATIONA |
|
| April 12, 2024 |
Employment Agreement of Lina Liu [English translation] EXHIBIT 10.3 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Employment Contract Party A: Yubo International Biotech (Beijing) Limited Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31 Xishiku Street, Xicheng District, Beijing Party B: Lina Liu ID Card No.: [***] Tel: [***] Address: [***] In accordance with the |
|
| April 12, 2024 |
Employment Agreement of Jun Wang [English translation] EXHIBIT 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Employment Contract Party A: Yubo International Biotech (Beijing) Limited Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31 Xishiku Street, Xicheng District, Beijing Party B: Jun Wang ID Card No.: [***] Tel: [***] Address: [***] In accordance with the |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended:December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| November 20, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21320 YUBO INTERNATI |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tran |
|
| August 11, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-21320 YUBO INTERNATIONAL |
|
| May 15, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATIONAL B |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATIONA |
|
| April 14, 2023 |
EXHIBIT 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED Lease Contract Lessor (hereinafter referred to as Party A): Sichuan Anyi Hengke Technology Co., Ltd. Mailing Address: [***] Business License Registration Number: [***] Legal Representative: Haomiao He Tel.: [***] Lessee (hereinafter referred to as Party B): Yubo Jingzhi Biotechnol |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended:December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi |
|
| December 7, 2022 |
EXHIBIT 10.2 AMENDMENT TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this ?Amendment?) is made as of the 6th day of December, 2022, and shall be effective as of September 2, 2022 (the ?Effective Date?), by and between YUBO INTERNATIONAL BIOTECH LIMITED, a New York corporation (the ?Company?), and WORLD PRECISION MEDICINE TECHNOLOGY LIMITED, a corporation organiz |
|
| December 7, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Yubo International Biotech Limited (Exact name of Registrant as Specified in Its Charter) New York 0-21320 11-3074326 (State or Other Jurisdiction of Incorporation |
|
| November 16, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATION |
|
| November 16, 2022 |
424B3 1 yubo424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-255805 Prospectus Supplement No. 2 (To Prospectus dated July 29, 2022) YUBO INTERNATIONAL BIOTECH LIMITED 5,000,000 Shares of Class A Common Stock Offered by our Company 12,251,100 Shares of Class A Common Stock Offered by the Selling Stockholders This Prospectus Supplement No. 2 (this “Prospectus Supplement”) supple |
|
| November 14, 2022 |
NT 10-Q 1 yubont10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Trans |
|
| November 10, 2022 |
YBGJ / Yubo International Biotech Ltd / Cheung Ho Shun - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Yubo International Biotech Limited (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 988366100 (CUSIP Number) November 9, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 10, 2022 |
EX-99.1 2 yuboex991.htm STOCK PURCHASE AGREEMENT EXHIBIT 99.1 CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH “[***]” TO INDICATE WHERE REDACTIONS HAVE BEEN MADE STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of September 23, 2022, is entered into by and among Focus D |
|
| November 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Yubo International Biotech Limited (Exact name of Registrant as Specified in Its Charter) New York 0-21320 11-3074326 (State or Other Jurisdiction of Incorporation) ( |
|
| November 10, 2022 |
EXHIBIT 99.4 CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH ?[***]? TO INDICATE WHERE REDACTIONS HAVE BEEN MADE. STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this ?Agreement?), dated as of September 23, 2022, is entered into by and among DragonCloud Technology Limited (the ?Selling Shareholde |
|
| November 10, 2022 |
YBGJ / Yubo International Biotech Ltd / Focus Draw Group Ltd - SC 13D/A Activist Investment SC 13D/A 1 yubosc13d.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Yubo International Biotech Limited (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 988366100 (CUSIP Number) Lina Liu Room 105, Building 5, 31 Xishiku Avenue Xicheng Distri |
|
| November 10, 2022 |
EXHIBIT 99.3 CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH ?[***]? TO INDICATE WHERE REDACTIONS HAVE BEEN MADE. STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this ?Agreement?), dated as of September 23, 2022, is entered into by and among DragonCloud Technology Limited (the ?Selling Shareholde |
|
| November 10, 2022 |
EXHIBIT 99.2 CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K AND, WHERE APPLICABLE, HAVE BEEN MARKED WITH ?[***]? TO INDICATE WHERE REDACTIONS HAVE BEEN MADE. STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this ?Agreement?), dated as of September 23, 2022, is entered into by and among Focus Draw Group Limited (the ?Selling Shareholder?), Y |
|
| September 9, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 Yubo International Biotech Limited (Exact name of Registrant as Specified in Its Charter) New York 0-21320 11-3074326 (State or Other Jurisdiction of Incorporation) |
|
| September 9, 2022 |
EXHIBIT 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is dated as of September 2, 2022, between Yubo International Biotech Limited, a New York corporation (the ?Company?), and the purchaser identified on the signature page hereto (including its succe |
|
| August 15, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATIONAL BI |
|
| August 15, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-255805 Prospectus Supplement No. 1 (To Prospectus dated July 29, 2022) YUBO INTERNATIONAL BIOTECH LIMITED 5,000,000 Shares of Class A Common Stock Offered by the Company 12,251,100 Shares of Class A Common Stock Offered by the Selling Stockholders This Prospectus Supplement No. 1 (this ?Prospectus Supplement?) supplements and amends our prospec |
|
| August 1, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-255805 PROSPECTUS YUBO INTERNATIONAL BIOTECH LIMITED 5,000,000 Shares of Class A Common Stock Offered by the Company 12,251,100 Shares of Class A Common Stock Offered by the Selling Stockholders We are offering, on a ?best efforts? basis, up to an aggregate of 5,000,000 shares of our Class A common stock, par value 0.001 per share, at a fixed p |
|
| July 27, 2022 |
CORRESP 1 filename1.htm YUBO INTERNATIONAL BIOTECH LIMITED Room 105, Building 5, 31 Xishiku Avenue Xicheng District, Beijing, China July 27, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Sasha Parikh Lynn Dicker Conlon Danberg Christine Westbrook Re: Yubo International Biotech Limited Registration Statement o |
|
| July 21, 2022 |
July 21, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Sasha Parikh Lynn Dicker Conlon Danberg Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 8 to Registration Statement on Form S-1 Filed July 8, 2022 File No. 333-255805 Ladies and Gentlemen: This letter is submitted on behalf of Yub |
|
| July 21, 2022 |
As filed with the Securities and Exchange Commission on July 21, 2022 As filed with the Securities and Exchange Commission on July 21, 2022 Registration No. |
|
| July 8, 2022 |
July 8, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Sasha Parikh Lynn Dicker Conlon Danberg Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 7 to Registration Statement on Form S-1 Filed June 10, 2022 File No. 333-255805 Ladies and Gentlemen: This letter is submitted on behalf of Yub |
|
| July 8, 2022 |
As filed with the Securities and Exchange Commission on July 8, 2022 As filed with the Securities and Exchange Commission on July 8, 2022 Registration No. |
|
| June 10, 2022 |
June 10, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: David Gessert Sasha Parikh Lynn Dicker Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 6 to Registration Statement on Form S-1 Filed April 20, 2022 File No. 333-255805 Ladies and Gentlemen: This letter is submitted on behalf of Yu |
|
| June 10, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1/A (Form Type) YUBO INTERNATIONAL BIOTECH LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Fees Previously Paid Equity Class A Common Stock, par value $0. |
|
| June 10, 2022 |
List of Subsidiaries of the Registrant EXHIBIT21.1 List of Subsidiaries of Yubo International Biotech Limited Legal Name of the Subsidiary Jurisdiction Platinum International Biotech Co., Ltd. Platinum International Biotech (Hong Kong) Limited Yubo International Biotech (Chengdu) Limited Yubo Global Biotechnology (Chengdu) Co., Ltd. Cayman Islands Hong Kong China China |
|
| June 10, 2022 |
As filed with the Securities and Exchange Commission on June 10, 2022 As filed with the Securities and Exchange Commission on June 10, 2022 Registration No. |
|
| May 16, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATIONAL B |
|
| April 20, 2022 |
CORRESP 85 filename85.htm April 20, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: David Gessert Sasha Parikh Lynn Dicker Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 5 to Registration Statement on Form S-1 Filed February 11, 2022 File No. 333-255805 Ladies and Gentlemen: This lette |
|
| April 20, 2022 |
EX-10.18 2 yuboex1018.htm SUPPLEMENTARY AGREEMENT EXHIBIT 10.18 Supplementary Agreement to The Exclusive Consulting Services Agreement This Supplementary Agreement to the Exclusive Consulting Services Agreement (this "Agreement") is made and entered into by and between the following parties on March 8, 2022 in Beijing, China. Party A: Yubo International Biotech (Chengdu) Limited Address: Room 201, |
|
| April 20, 2022 |
EXHIBIT 99.2 YUBO INTERNATIONAL BIOTECH LIMITED AND SUBSIDIARIES AND VARIABLE INTEREST ENTITY CONDENSED CONSOLIDATING BALANCE SHEET As of December 31, 2020 (Expressed in US Dollars) Yubo International Biotech (Parent) Yubo International Biotech (Beijing) Limited. (VIE) Others (Holding companies) Adjustments Consolidated ASSETS Current assets Cash $ - 746,613 $ 635,912 - $ 1,382,525 Receivables - 2 |
|
| April 20, 2022 |
As filed with the Securities and Exchange Commission on April 20, 2022 As filed with the Securities and Exchange Commission on April 20, 2022 Registration No. |
|
| April 20, 2022 |
EX-FILING FEES 5 yuboex107.htm FEE TABLE EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1/A (Form Type) YUBO INTERNATIONAL BIOTECH LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggreg |
|
| April 15, 2022 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATIONAL BIOTECH |
|
| March 24, 2022 |
NT 10-K 1 yubont10k.htm FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ T |
|
| February 11, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) YUBO INTERNATIONAL BIOTECH LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Fees Previously Paid Equity Class A Common Stock, par value $0. |
|
| February 11, 2022 |
February 11, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: David Gessert Sasha Parikh Lynn Dicker Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 4 to Registration Statement on Form S-1 Filed December 9, 2021 File No. 333-255805 Ladies and Gentlemen: This letter is submitted on behalf |
|
| February 11, 2022 |
As filed with the Securities and Exchange Commission on February 11, 2022 As filed with the Securities and Exchange Commission on February 11, 2022 Registration No. |
|
| December 9, 2021 |
EX-10.3 4 yuboex103.htm EMPLOYMENT AGREEMENT EXHIBIT 10.3 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Employment Contract Party A: Platinum International Biotechnology (Beijing) Co., Ltd. Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31 Xishiku Street, Xicheng District, Beijing Party B: Lina Liu ID Card No. |
|
| December 9, 2021 |
As filed with the Securities and Exchange Commission on December 9, 2021 As filed with the Securities and Exchange Commission on December 9, 2021 Registration No. |
|
| December 9, 2021 |
EX-10.2 3 yuboex102.htm EMPLOYMENT AGREEMENT EXHIBIT 10.2 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Employment Contract Party A: Platinum International Biotechnology (Beijing) Co., Ltd. Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31 Xishiku Street, Xicheng District, Beijing Party B: Yang Wang ID Card No |
|
| December 9, 2021 |
EX-10.1 2 yuboex101.htm EMPLOYMENT AGREEMENT EXHIBIT 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Employment Contract Party A: Platinum International Biotechnology (Beijing) Co., Ltd. Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31 Xishiku Street, Xicheng District, Beijing Party B: Jun Wang ID Card No. |
|
| December 9, 2021 |
CORRESP 86 filename86.htm December 9, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: David Gessert Sasha Parikh Lynn Dicker Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 3 to Registration Statement on Form S-1 Filed October 12, 2021 File No. 333-255805 Ladies and Gentlemen: This lett |
|
| November 15, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATION |
|
| October 12, 2021 |
As filed with the Securities and Exchange Commission on October 12, 2021 As filed with the Securities and Exchange Commission on October 12, 2021 Registration No. |
|
| October 12, 2021 |
October 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: David Gessert Sasha Parikh Lynn Dicker Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 2 to Registration Statement on Form S-1 Filed August 3, 2021 File No. 333-255805 Ladies and Gentlemen: This letter is submitted on behalf of |
|
| October 12, 2021 |
EX-99.1 3 yuboex991.htm PRO FORMA FINANCIAL STATEMENTS EXHIBIT 99.1 YUBO INTERNATIONAL BIOTECH LIMITED AND SUBSIDIARIES AND VARIABLE INTEREST ENTITY PROFORMA COMBINED BALANCE SHEETS As of December 31, 2020 (Expressed in US Dollars) Yubo International Biotech (Parent) Yubo International Biotech (Beijing) Limited. (VIE) Others (Holding companies)1 Proforma Adjustments Proforma Combined ASSETS Curren |
|
| August 20, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 YUBO INTERNATIONAL BI |
|
| August 16, 2021 |
NT 10-Q 1 yubont10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition |
|
| August 3, 2021 |
As filed with the Securities and Exchange Commission on August 3, 2021 As filed with the Securities and Exchange Commission on August 3, 2021 Registration No. |
|
| August 3, 2021 |
August 3, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: David Gessert Sasha Parikh Lynn Dicker Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 1 to Registration Statement on Form S-1 Filed July 12, 2021 File No. 333-255805 Ladies and Gentlemen: This letter is submitted on behalf of Yu |
|
| July 12, 2021 |
Agreement and Plan of Share Exchange, dated January 14, 2021 EX-2.1 2 yuboex21.htm EX-2.1 EXHIBIT 2.1 AGREEMENT AND PLAN OF SHARE EXCHANGE THIS AGREEMENT AND PLAN OF SHARE EXCHANGE (this “Agreement”) is made this 13th day of January, 2021 (the “Effective Date”), by and among YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (“Pubco”), on the one hand, and YUBO INTERNATIONAL BIOTECH (BEIJING) LIMITED, a company organized unde |
|
| July 12, 2021 |
EX-10.16 3 yuboex1016.htm EX-10.16 EXHIBIT 10.16 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PROPERTY LEASE CONTRACT (Contract No.: LKTZ-SYEQA-BGZL-2020-00X) Lessor (hereinafter referred to as Party A): Chengdu Liankang Investment Co., Ltd. Mailing Address: No. 38, North Section, Eighth First Road, Yongning Town, Wenjiang District, Chen |
|
| July 12, 2021 |
As filed with the Securities and Exchange Commission on July 12 , 2021 S-1/A 1 yubos1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on July 12 , 2021 Registration No. 333 - 255805 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 YUBO INTERNATIONAL BIOTECH LIMITED (Exact Name of Registrant as Specified in its Charter) New York 0-21320 11-30 |
|
| July 12, 2021 |
EX-10.17 4 yuboex1017.htm EX-10.17 EXHIBIT 10.17 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED SUPPLEMENTAL AGREEMENT TO LEASE (Agreement No.: LKTZ-SYEQA-BCXY-2021-001) Lessor (hereinafter referred to as Party A): Chengdu Liankang Investment Co., Ltd. Mailing Address: No. 38, North Section, Eighth First Road, Yongning Town, Wenjiang Distr |
|
| July 12, 2021 |
July 12, 2021 SUBMISSION VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: David Gessert Sasha Parikh Lynn Dicker Christine Westbrook Re: Yubo International Biotech Limited Amendment No. 1 to Registration Statement on Form S-1 CIK No. 000895464 File No. 333-255805 Ladies and Gentlemen: This letter is submitted on beha |
|
| May 24, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 yubo10q.htm FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| May 24, 2021 |
EXHIBIT 10.17 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED SUPPLEMENTAL AGREEMENT TO LEASE (Agreement No.: LKTZ-SYEQA-BCXY-2021-001) Lessor (hereinafter referred to as Party A): Chengdu Liankang Investment Co., Ltd. Mailing Address: No. 38, North Section, Eighth First Road, Yongning Town, Wenjiang District, Chengdu Business License Regis |
|
| May 24, 2021 |
EXHIBIT 10.16 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED PROPERTY LEASE CONTRACT (Contract No.: LKTZ-SYEQA-BGZL-2020-00X) Lessor (hereinafter referred to as Party A): Chengdu Liankang Investment Co., Ltd. Mailing Address: No. 38, North Section, Eighth First Road, Yongning Town, Wenjiang District, Chengdu Business License Registration N |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 CUSIP NUMBER 988366100 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transiti |
|
| May 6, 2021 |
EX-10.9 13 yuboex109.htm EX-10.9 EXHIBIT 10.9 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Cooperation Agreement Party A: Beijing Zhenxigu Medical Research Center (L.P.) Party B: Yubo International Biotech (Beijing) Limited Party C: Huailai Huayue Hengsheng Medical Device Co., Ltd. Through friendly consultations, the Parties hereby agre |
|
| May 6, 2021 |
EX-10.6 10 yuboex106.htm EX-10.6 EXHIBIT 10.6 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. EXCLUSIVE CONSULTING SERVICE AGREEMENT This Exclusive Consulting Service Agreement (this "Agreement") is made and entered into by and between the following parties on September 11, 2020 in Beijing, PRC. Party A: Yubo International Biotech (Chengdu |
|
| May 6, 2021 |
Letter from RBSM LLP, dated October 15, 2020 EX-16.1 20 yuboex161.htm EX-16.1 EXHIBIT 16.1 October 15, 2020 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 – 7561 Re: MAGNA-LAB INC. Commission File Number 0-21320 Ladies and Gentlemen: We have read Item 4.01 of MAGNA-LAB INC.’s Form 8-K dated October 13, 2020 and we agree with the statements made regarding our firm. We have no basis to agree or disagree with ot |
|
| May 6, 2021 |
EX-10.5 9 yuboex105.htm EX-10.5 EXHIBIT 10.5 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Exclusive Option Agreement This Exclusive Option Agreement (this "Agreement") is executed by and among the following Parties on September 11, 2020 in Beijing, PRC: Party A: Yobo International Biotech (Chengdu) Limited Registered Address: 1201, 12 / |
|
| May 6, 2021 |
EX-10.11 15 yuboex1011.htm EX-10.11 EXHIBIT 10.11 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. JIUSI CULTURAL CREATIVE PARK LEASE CONTRACT Party A: JIUSICHENG INVESTMENT MANAGEMENT (BEIJING) CO., LTD. Party B: YUBO INTERNATIONAL BIOTECH (BEIJING) LIMITED - 1 - 九思成投资管理（北京）有限公司 北京市西城区西什库大街 31 号院九思文创园 LEASE CONTRACT Lessor: JIUSICHENG INVE |
|
| May 6, 2021 |
EX-10.10 14 yuboex1010.htm EX-10.10 EXHIBIT 10.10 Loan Contract Party A: Yubo International Biotech (Beijing) Limited (hereinafter referred to as "Party A") Address: Building 5, Yard 31, Xishiku Street, Xicheng District, Beijing Legal Representative: Jun Wang Party B: Beijing Zhenhuikang Biotechnology Co., Ltd. (hereinafter referred to as "Party B") Address: Room 202, 2/F, Building 23, No. 31, Xis |
|
| May 6, 2021 |
Employment Agreement, dated December 1, 2020, by and between Yubo and Jun Wang (English Translation) EX-10.1 5 yuboex101.htm EX-10.1 EXHIBIT 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Labor Contract Party A: Yubo International Biotech (Beijing) Limited Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31, Xishiku Da Jie, Xicheng District, Beijing Party B: Jun Wang Chinese Identification No.: [*********** |
|
| May 6, 2021 |
EXHIBIT 10.7 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Entrustment Technical Service Agreement This Entrustment Technical Service Agreement (this ?Agreement?) is made by and between the following two parties on February 27, 2020 in Beijing: Party A: Yubo International Biotech (Beijing) Limited Address: Building 5, Yard 31, Xishiku St |
|
| May 6, 2021 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on May 5, 2021 Registration No. |
|
| May 6, 2021 |
EXHIBIT 3.2 BYLAWS OF YUBO INTERNATIONAL BIOTECH LIMITED (A NEW YORK CORPORATION) Dated: October 14, 2020 -1- YUBO INTERNATIONAL BIOTECH LIMITED BYLAWS ARTICLE ONE OFFICES Section 1. Registered Office. The registered office of YUBO International Biotech Limited, a New York corporation (the ?Corporation?), shall be within the State of New York in the County of New York, unless otherwise designated |
|
| May 6, 2021 |
EXHIBIT 10.2 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Labor Contract Party A: Yubo International Biotech (Beijing) Limited. Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31, Xishiku Street, Xicheng District, Beijing Party B: Yang Wang Chinese Identification No.: [***********] Tel: [***********] Residence |
|
| May 6, 2021 |
Indemnification Agreement by and between the Registrant and Yang Wang EX-10.13 17 yuboex1013.htm EX-10.13 EXHIBIT 10.13 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of January , 2021, is made by and between YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (the “Company”), and the undersigned, who is either a director or an officer of the Company (the “Indemnitee”), with this Agreement to be d |
|
| May 6, 2021 |
Employment Agreement, dated October 10, 2020, by and between Yubo and Lina Liu (English Translation) EXHIBIT 10.3 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Labor Contract Party A: Yubo International Biotech (Beijing) Limited. Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31, Xishiku Street, Xicheng District, Beijing Party B: Lina Liu Chinese Identification No.: [***********] Tel: [***********] Residence |
|
| May 6, 2021 |
Indemnification Agreement by and between the Registrant and Lina Liu EX-10.15 19 yuboex1015.htm EX-10.15 EXHIBIT 10.15 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of January , 2021, is made by and between YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (the “Company”), and the undersigned, who is either a director or an officer of the Company (the “Indemnitee”), with this Agreement to be d |
|
| May 6, 2021 |
Indemnification Agreement by and between the Registrant and Jun Wang EX-10.12 16 yuboex1012.htm EX-10.12 EXHIBIT 10.12 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of January , 2021, is made by and between YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (the “Company”), and the undersigned, who is either a director or an officer of the Company (the “Indemnitee”), with this Agreement to be d |
|
| May 6, 2021 |
Articles of Incorporation of Registrant, as amended EX-3.1 2 yuboex31.htm EX-3.1 EXHIBIT 3.1 |
|
| May 6, 2021 |
EXHIBIT 10.8 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. AGREEMENT OF JOINT RESEARCH AND DEVELOPMENT Party A: Beijing Zhenxigu Medical Research Center (L.P.) Party B: Yubo International Biotech (Beijing) Limited WHEREAS: Party A is a high-tech R&D center in the biomedicine field, which owns numerous core patent technologies and GMP sta |
|
| May 6, 2021 |
EX-10.4 8 yuboex104.htm EX-10.4 EXHIBIT 10.4 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Equity Pledge Agreement This Equity Pledge Agreement (this “Agreement”) has been executed by and among the following parties on September 11, 2020 in Beijing: Party A: Yubo International Biotech (Chengdu) Limited. (the “Pledgee”) Registered Address |
|
| May 6, 2021 |
Indemnification Agreement by and between the Registrant and Zhihui Bai EX-10.14 18 yuboex1014.htm EX-10.14 EXHIBIT 10.14 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of January , 2021, is made by and between YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (the “Company”), and the undersigned, who is either a director or an officer of the Company (the “Indemnitee”), with this Agreement to be d |
|
| April 23, 2021 |
10-KT 1 yubo10kt.htm FORM 10-KT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KT (Mark One) ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☒ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from March 1, 2020 to December 3 |
|
| April 19, 2021 |
Financial Statements and Exhibits 8-K/A 1 yubo8ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 14, 2021 YUBO INTERNATIONAL BIOTECH LIMITED (Exact Name of Registrant as Specified in its Charter) New York 0-21320 11-30743 |
|
| April 19, 2021 |
EXHIBIT 99.1 PLATINUM INTERNATONAL BIOTECH CO., LTD AND SUBSIDIARIES AND VARIABLE INTEREST ENTITY INDEX TO CONSOLIDATED FINANCIAL STATEMENTS For the years ended December 31, 2020 and December 31, 2019 Table of Contents Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations and Comprehensive Loss F-4 Consolidated Statements |
|
| April 13, 2021 |
Articles of Incorporation of Registrant, as amended (2) EXHIBIT 3.1 |
|
| April 13, 2021 |
8-K 1 yubo8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 13, 2021 YUBO INTERNATIONAL BIOTECH LIMITED (Exact Name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or other jurisdic |
|
| March 24, 2021 |
DEF 14C 1 yubodef14c.htm DEF 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14C INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☒ Definitive Information Statement ☐ Confidential, of the Use of the Commission Only (as permitted by Rule 14c-5 |
|
| March 12, 2021 |
PRE 14C 1 yubopre14c.htm PRE 14C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14C INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☑ Preliminary Information Statement ☐ Definitive Information Statement ☐ Confidential, of the Use of the Commission Only (as permitted by Rule 14c-5 |
|
| February 5, 2021 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 4, 2021 YUBO INTERNATIONAL BIOTECH LIMITED (Exact Name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or other jurisdiction of incorporation) ( |
|
| January 25, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Yubo International Biotech Limited (Name of Issuer) Class A Common Stock, $.001 par value (Title of Class of Securities) 988366100 (CUSIP Number) Chinaone Technology Limited Wickham’s Cay II, P.O. Box 2221 Road Town, Tortola, British Virgin Islands (Name, Address, and Telephone Number o |
|
| January 21, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Yubo International Biotech Limited (Name of Issuer) Class A Common Stock, $.001 par value (Title of Class of Securities) 988366100 (CUSIP Number) Focus Draw Group Limited Wickham’s Cay II, P.O. Box 2221 Road Town, Tortola, British Virgin Islands (Name, Address, and Telephone Number of P |
|
| January 21, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Yubo International Biotech Limited (Name of Issuer) Class A Common Stock, $.001 par value (Title of Class of Securities) 988366100 (CUSIP Number) Focusone Technology Group Limited Wickham’s Cay II, P.O. Box 2221 Road Town, Tortola, British Virgin Islands (Name, Address, and Telephone Nu |
|
| January 21, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Yubo International Biotech Limited (Name of Issuer) Class A Common Stock, $.001 par value (Title of Class of Securities) 988366100 (CUSIP Number) Boao Biotech Limited Wickham’s Cay II, P.O. Box 2221 Road Town, Tortola, British Virgin Islands (Name, Address, and Telephone Number of Perso |
|
| January 21, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Yubo International Biotech Limited (Name of Issuer) Class A Common Stock, $.001 par value (Title of Class of Securities) 988366100 (CUSIP Number) Flydragon International Limited Wickham’s Cay II, P.O. Box 2221 Road Town, Tortola, British Virgin Islands (Name, Address, and Telephone Numb |
|
| January 20, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 Yubo International Biotech Limited (Name of Issuer) Class A Common Stock, $.001 par value (Title of Class of Securities) 988366100 (CUSIP Number) Lina Liu c/o Yubo International Biotech Limited, Inc. Room 105, Building 5, 31 Xishiku Avenue, Xicheng District, Beijing, China 010-6615 51 |
|
| January 19, 2021 |
10-Q 1 yubo10q.htm FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num |
|
| January 15, 2021 |
NT 10-Q 1 yubont10q.htm NT 10-Q Form 12b-25. - NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR For Period Ended: November 30, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report |
|
| January 14, 2021 |
EXHIBIT 10.8 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. AGREEMENT OF JOINT RESEARCH AND DEVELOPMENT Party A: Beijing Zhenxigu Medical Research Center (L.P.) Party B: Yubo International Biotech (Beijing) Limited WHEREAS: Party A is a high-tech R&D center in the biomedicine field, which owns numerous core patent technologies and GMP sta |
|
| January 14, 2021 |
EXHIBIT 3.2 BYLAWS OF YUBO INTERNATIONAL BIOTECH LIMITED (A NEW YORK CORPORATION) Dated: October 14, 2020 YUBO INTERNATIONAL BIOTECH LIMITED BYLAWS ARTICLE ONE OFFICES Section 1. Registered Office. The registered office of YUBO International Biotech Limited, a New York corporation (the “Corporation”), shall be within the State of New York in the County of New York, unless otherwise designated by t |
|
| January 14, 2021 |
EX-10.9 13 yuboex109.htm EX-10.9 EXHIBIT 10.9 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Cooperation Agreement Party A: Beijing Zhenxigu Medical Research Center (L.P.) Party B: Yubo International Biotech (Beijing) Limited Party C: Huailai Huayue Hengsheng Medical Device Co., Ltd. Through friendly consultations, the Parties hereby agre |
|
| January 14, 2021 |
Indemnification Agreement by and between the Registrant and Lina Liu EX-10.15 19 yuboex1015.htm EX-10.15 EXHIBIT 10.15 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of January 14, 2021, is made by and between YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (the “Company”), and the undersigned, who is either a director or an officer of the Company (the “Indemnitee”), with this Agreement to be |
|
| January 14, 2021 |
EX-10.7 11 yuboex107.htm EX-10.7 EXHIBIT 10.7 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Entrustment Technical Service Agreement This Entrustment Technical Service Agreement (this “Agreement”) is made by and between the following two parties on February 27, 2020 in Beijing: Party A: Yubo International Biotech (Beijing) Limited Address |
|
| January 14, 2021 |
Employment Agreement, dated October 10, 2020, by and between Yubo and Lina Liu (English Translation) EX-10.3 7 yuboex103.htm EX-10.3 EXHIBIT 10.3 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Labor Contract Party A: Yubo International Biotech (Beijing) Limited. Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31, Xishiku Street, Xicheng District, Beijing Party B: Lina Liu Chinese Identification No.: [********** |
|
| January 14, 2021 |
Agreement and Plan of Share Exchange, dated January 14, 2021(1) EX-2.1 2 yuboex21.htm EX-2.1 EXHIBIT 2.1 AGREEMENT AND PLAN OF SHARE EXCHANGE THIS AGREEMENT AND PLAN OF SHARE EXCHANGE (this “Agreement”) is made this 14th day of January, 2021 (the “Effective Date”), by and among YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (“Pubco”), on the one hand, and YUBO INTERNATIONAL BIOTECH (BEIJING) LIMITED, a company organized unde |
|
| January 14, 2021 |
EX-10.6 10 yuboex106.htm EX-10.6 EXHIBIT 10.6 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. EXCLUSIVE CONSULTING SERVICE AGREEMENT This Exclusive Consulting Service Agreement (this “Agreement”) is made and entered into by and between the following parties on September 11, 2020 in Beijing, PRC. Party A: Yubo International Biotech (Chengdu |
|
| January 14, 2021 |
EX-10.5 9 yuboex105.htm EX-10.5 EXHIBIT 10.5 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Exclusive Option Agreement This Exclusive Option Agreement (this “Agreement”) is executed by and among the following Parties on September 11, 2020 in Beijing, PRC: Party A: Yobo International Biotech (Chengdu) Limited Registered Address: 1201, 12 / |
|
| January 14, 2021 |
EX-10.4 8 yuboex104.htm EX-10.4 EXHIBIT 10.4 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Equity Pledge Agreement This Equity Pledge Agreement (this “Agreement”) has been executed by and among the following parties on September 11, 2020 in Beijing: Party A: Yubo International Biotech (Chengdu) Limited. (the “Pledgee”) Registered Address |
|
| January 14, 2021 |
Articles of Incorporation of Registrant, as amended (1) EX-3.1 3 yuboex31.htm EX-3.1 EXHIBIT 3.1 |
|
| January 14, 2021 |
Indemnification Agreement by and between the Registrant and Yang Wang EX-10.13 17 yuboex1013.htm EX-10.13 EXHIBIT 10.13 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of January 14, 2021, is made by and between YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (the “Company”), and the undersigned, who is either a director or an officer of the Company (the “Indemnitee”), with this Agreement to be |
|
| January 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 YUBO INTERNATIONAL BIOTECH LIMITED (Exact name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or Other Jurisdiction of Incorporation) ( |
|
| January 14, 2021 |
EXHIBIT 99.2 YUBO INTERNATIONAL BIOTECH LIMITED (Formerly Magna-Lab Inc.) AND SUBSIDIARIES AND VARIABLE INTEREST ENTITY Index to Pro Forma Combined Financial Statements Table of Contents Pro Forma Combined Balance Sheets as of September 30, 2020 (Unaudited) PF-1 Pro Forma Combined Statements of Operations and Comprehensive Loss (Unaudited): For the year ended December 31, 2019 PF-2 For the nine mo |
|
| January 14, 2021 |
EX-99.1 20 yuboex991.htm EX-99.1 EXHIBIT 99.1 PLATINUM INTERNATONAL BIOTECH CO., LTD AND SUBSIDIARIES AND VARIABLE INTEREST ENTITY INDEX TO CONSOLIDATED FINANCIAL STATEMENTS For the nine months ended September 30, 2020 and September 30, 2019 (unaudited) and for the years ended December 31, 2019 and December 31, 2018 Table of Contents Report of Independent Registered Public Accounting Firm F-1 Cons |
|
| January 14, 2021 |
EX-10.2 6 yuboex102.htm EX-10.2 EXHIBIT 10.2 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Labor Contract Party A: Yubo International Biotech (Beijing) Limited. Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31, Xishiku Street, Xicheng District, Beijing Party B: Yang Wang Chinese Identification No.: [********* |
|
| January 14, 2021 |
EXHIBIT 10.11 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. JIUSI CULTURAL CREATIVE PARK LEASE CONTRACT Party A: JIUSICHENG INVESTMENT MANAGEMENT (BEIJING) CO., LTD. Party B: YUBO INTERNATIONAL BIOTECH (BEIJING) LIMITED 九思成投资管理（北京）有限公司 北京市西城区西什库大街 31 号院九思文创园 LEASE CONTRACT Lessor: JIUSICHENG INVESTMENT MANAGEMENT (BEIJING) CO., LTD. Addr |
|
| January 14, 2021 |
EX-10.10 14 yuboex1010.htm EX-10.10 EXHIBIT 10.10 Loan Contract Party A: Yubo International Biotech (Beijing) Limited (hereinafter referred to as “Party A”) Address: Building 5, Yard 31, Xishiku Street, Xicheng District, Beijing Legal Representative: Jun Wang Party B: Beijing Zhenhuikang Biotechnology Co., Ltd. (hereinafter referred to as “Party B”) Address: Room 202, 2/F, Building 23, No. 31, Xis |
|
| January 14, 2021 |
Employment Agreement, dated October 10, 2020, by and between Yubo and Jun Wang (English Translation) EX-10.1 5 yuboex101.htm EX-10.1 EXHIBIT 10.1 CERTAIN PERSONALLY IDENTIFIABLE INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED. Labor Contract Party A: Yubo International Biotech (Beijing) Limited Legal Representative: Jun Wang Business Address: Room 108, Building 6, No. 31, Xishiku Street, Xicheng District, Beijing Party B: Jun Wang Chinese Identification No.: [*********** |
|
| January 14, 2021 |
Indemnification Agreement by and between the Registrant and Jun Wang EXHIBIT 10.12 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of January 14, 2021, is made by and between YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (the “Company”), and the undersigned, who is either a director or an officer of the Company (the “Indemnitee”), with this Agreement to be deemed effective as of the date tha |
|
| January 14, 2021 |
Indemnification Agreement by and between the Registrant and Zhihui Bai EX-10.14 18 yuboex1014.htm EX-10.14 EXHIBIT 10.14 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”), dated as of January 14, 2021, is made by and between YUBO INTERNATIONAL BIOTECH LIMITED (f/k/a Magna-Lab, Inc.), a New York corporation (the “Company”), and the undersigned, who is either a director or an officer of the Company (the “Indemnitee”), with this Agreement to be |
|
| December 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 4, 2020 YUBO INTERNATIONAL BIOTECH LIMITED (Exact Name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or other jurisdiction of incorporation) ( |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☐ Preliminary Information Statement ☒ Definitive Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Magna-Lab, Inc. (Name of R |
|
| November 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION STATEMENT Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ☒ Preliminary Information Statement ☐ Definitive Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) Magna-Lab, Inc. (Name of R |
|
| October 20, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exa |
|
| October 16, 2020 |
Letter from RBSM LLP, dated October 15, 2020 (24) Exhibit 16.1 October 15, 2020 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 – 7561 Re: MAGNA-LAB INC. Commission File Number 0-21320 Ladies and Gentlemen: We have read Item 4.01 of MAGNA-LAB INC.’s Form 8-K dated October 13, 2020 and we agree with the statements made regarding our firm. We have no basis to agree or disagree with other statements contained therein. |
|
| October 16, 2020 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 13, 2020 MAGNA-LAB INC. (Exact Name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 15, 2020 |
MAGAA / Magna-Lab, Inc. / Liu Lina - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Magna-Lab, Inc. (Name of Issuer) Series A Common Stock, $.001 par value (Title of Class of Securities) 559235403 (CUSIP Number) Lina Liu c/o Magna-Lab, Inc. Room 105, Building 5, 31 Xishiku Avenue, Xicheng District, Beijing, China +86 (010) 6615-5141 (Name, Address, and Telephone Number of Person Authorized to Receive Notices a |
|
| October 15, 2020 |
Form 12b-25. - NOTIFICATION OF LATE FILING SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR For Period Ended: August 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report o |
|
| October 5, 2020 |
AMENDED AND RESTATED STOCK PURCHASE AGREEMENT AMENDED AND RESTATED STOCK PURCHASE AGREEMENT Amended and Restated Stock Purchase Agreement, dated as of September 23, 2020 (the "Amendment"), is by, between and among Activist Investing, LLC. |
|
| October 5, 2020 |
Entry into a Material Definitive Agreement - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 MAGNA-LAB, INC. (Exact name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or Other Jurisdiction of Incorporation) (Commission file Numb |
|
| September 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(f) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER MAGNA-LAB, INC. (Name of Registrant) New York 000-21320 20-0956471 State of Incorporation) (Commission File No.) (IRS Employer Identification No. 1185 Avenue of the Americas, 3rd Floor New York, NY 10036 (Address of |
|
| July 20, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exact |
|
| July 15, 2020 |
Form 12b-25. - NOTIFICATION OF LATE FILING FORM 12b-25 SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR For Period Ended: May 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition |
|
| July 9, 2020 |
Entry into a Material Definitive Agreement 8-K 1 e6197598k-magna.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 2, 2020 MAGNA-LAB, INC. (Exact name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or Other Jurisdiction of Incorporation) |
|
| July 9, 2020 |
STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of this 30th day of June, 2020, summarizes the basic terms and conditions by and among Magna-Lab, Inc. |
|
| July 9, 2020 |
THIS AMENDMENT TO STOCK PURCHASE AGREEMENT (the “Amendment”) is entered into as of this 2nd day of July, 2020, by and among Magna-Lab, Inc. |
|
| July 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INFORMATION STATEMENT PURSUANT TO SECTION 14(f) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 14f-1 THEREUNDER MAGNA-LAB, INC. (Name of Registrant) New York 000-21320 20-0956471 State of Incorporation) (Commission File No.) (IRS Employer Identification No. 1662 Old Country Road, # 355 Plainview, NY 1180 (Address of Principal |
|
| June 25, 2020 |
Note Payable to Joel Kanter dated June 4, 2020 (21) PROMISSORY NOTE $5,000.00 June 4, 2020 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Five Thousand Dollars (US$5,000), together with |
|
| June 25, 2020 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended February 29, 2020 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exact Name |
|
| June 25, 2020 |
Note Payable to Joel Kanter dated April 17, 2020 (21) PROMISSORY NOTE $2,750.00 April 17, 2020 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Two Thousand Seven Hundred Fifty Dollars (US$2 |
|
| June 25, 2020 |
Note Payable to Joel Kanter dated June 23, 2020 (21) PROMISSORY NOTE $4,750.00 June 23, 2020 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Four Thousand Seven Hundred Fifty Dollars (US$4 |
|
| May 29, 2020 |
8-K 1 e6196688k-magna.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 29, 2020 MAGNA-LAB, INC. (Exact name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or Other Jurisdiction of Incorporation) |
|
| January 13, 2020 |
MAGAA / Magna-Lab, Inc. 10-Q - Quarterly Report - U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (E |
|
| January 13, 2020 |
Note Payable to Joel Kanter dated November 4, 2019*** PROMISSORY NOTE $3,000.00 November 4, 2019 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Three Thousand Dollars (US$3,000), together |
|
| October 11, 2019 |
Note Payable to Joel Kanter dated July 8, 2019** PROMISSORY NOTE $3,500.00 July 8, 2019 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Three Thousand Five Hundred Dollars (US$3,500), |
|
| October 11, 2019 |
MAGAA / Magna-Lab, Inc. 10-Q - Quarterly Report - 10-Q 1 e61910910q-magna.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| July 11, 2019 |
MAGAA / Magna-Lab, Inc. 10-Q - Quarterly Report - U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exact |
|
| July 11, 2019 |
Note Payable to Joel Kanter dated May 20, 2019* EX-10.76 2 e618546ex10-76.htm PROMISSORY NOTE $10,000.00 May 20, 2019 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Ten Thousand Doll |
|
| June 12, 2019 |
Note Payable to Magna Acquisition LLC dated December 4, 2018 (17) PROMISSORY NOTE $7.600.00 December 4, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Seven Thousand Six Hundred Dollars (US$7,600 |
|
| June 12, 2019 |
MAGAA / Magna-Lab, Inc. 10-K - Annual Report - U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended February 28, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exact Name |
|
| May 30, 2019 |
MAGAA / Magna-Lab, Inc. NT 10-K - - Form 12b-25. - NOTIFICATION OF LATE FILING FORM 12b-25 SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR For Period Ended: February 28, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Trans |
|
| January 11, 2019 |
Note Payable to Magna Acquisition LLC dated October 9, 2018 (16) EX-10.74 2 e618142ex10-74.htm PROMISSORY NOTE $3,400.00 October 9, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Three Thousand |
|
| January 11, 2019 |
MAGAA / Magna-Lab, Inc. 10-Q (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (E |
|
| October 12, 2018 |
Note Payable to Magna Acquisition LLC dated July 3, 2018 (15) PROMISSORY NOTE $3,500.00 July 3, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Three Thousand Five Hundred Dollars (US$3,500), |
|
| October 12, 2018 |
MAGAA / Magna-Lab, Inc. 10-Q (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exa |
|
| October 12, 2018 |
Note Payable to Magna Acquisition LLC dated June 7, 2018 (15) PROMISSORY NOTE $3,000.00 June 7, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Three Thousand Dollars (US$3,000), together with |
|
| July 16, 2018 |
Note Payable to Magna Acquisition LLC dated April 3, 2018. (14) PROMISSORY NOTE $1,000.00 April 3, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of One Thousand Dollars (US$1,000), together with |
|
| July 16, 2018 |
Note Payable to Magna Acquisition LLC dated April 30, 2018. (14) PROMISSORY NOTE $1,500.00 April 30, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Fifteen Hundred Dollars (US$1,500), together w |
|
| July 16, 2018 |
Note Payable to Magna Acquisition LLC dated March 6, 2018. (14) PROMISSORY NOTE $3,500.00 March 6, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Thirty Five Hundred Dollars (US$3,500), togethe |
|
| July 16, 2018 |
MAGAA / Magna-Lab, Inc. 10-Q (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exact |
|
| July 16, 2018 |
Note Payable to Magna Acquisition LLC dated May 18, 2018. (14) PROMISSORY NOTE $10,000.00 May 18, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Ten Thousand Dollars (US$10,000), together with |
|
| June 13, 2018 |
Note Payable to Magna Acquisition LLC dated December 5, 2017. (13) EX-10.65 3 e618088ex10-65.htm PROMISSORY NOTE $2,500.00 December 5, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hu |
|
| June 13, 2018 |
Note Payable to Magna Acquisition LLC dated December 1, 2017. (13) PROMISSORY NOTE $64,000.00 December 1, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Sixty Four Thousand Dollars (US$64,000), to |
|
| June 13, 2018 |
MAGAA / Magna-Lab, Inc. 10-K (Annual Report) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended February 28, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Name of re |
|
| June 13, 2018 |
Note Payable to Magna Acquisition LLC dated January 2, 2018. (13) PROMISSORY NOTE $2,500.00 January 2, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hundred Dollars (US$2,500), toget |
|
| June 13, 2018 |
Note Payable to Magna Acquisition LLC dated January 29, 2018. (13) PROMISSORY NOTE $5,000.00 January 29, 2018 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Five Thousand Dollars (US$5,000), together w |
|
| May 30, 2018 |
MAGAA / Magna-Lab, Inc. NT 10-K Form 12b-25. - NOTIFICATION OF LATE FILING FORM 12b-25 SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-SAR For Period Ended: February 28, 2018 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Trans |
|
| January 16, 2018 |
MAGAA / Magna-Lab, Inc. 10-Q (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (E |
|
| January 16, 2018 |
Note Payable to Magna Acquisition LLC dated November 6, 2017. (12) PROMISSORY NOTE $2,500.00 November 6, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hundred Dollars (US$2,500), toge |
|
| January 16, 2018 |
Note Payable to Magna Acquisition LLC dated October 16, 2017. (12) PROMISSORY NOTE $5,750.00 October 16, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Fifty Seven Hundred Fifty Dollars (US$5,750) |
|
| January 16, 2018 |
Note Payable to Magna Acquisition LLC dated October 3, 2017. (12) PROMISSORY NOTE $2,500.00 October 3, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hundred Dollars (US$2,500), toget |
|
| October 16, 2017 |
Note Payable to Magna Acquisition LLC dated June 13, 2017.(11) PROMISSORY NOTE $6,000.00 June 13, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Five Thousand Five Hundred Dollars (US$6,000), |
|
| October 16, 2017 |
Note Payable to Magna Acquisition LLC dated July 13, 2017. (11) PROMISSORY NOTE $3,000.00 July 13, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Three Thousand Dollars (US$3,000), together wit |
|
| October 16, 2017 |
Note Payable to Magna Acquisition LLC dated July 31, 2017. (11) PROMISSORY NOTE $2,500.00 July 31, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Two Thousand Five Hundred Dollars (US$2,500), t |
|
| October 16, 2017 |
Note Payable to Magna Acquisition LLC dated June 29, 2017. (11) PROMISSORY NOTE $3,000.00 June 29, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Three Thousand Dollars (US$3,000), together wit |
|
| October 16, 2017 |
MAGAA / Magna-Lab, Inc. 10-Q (Quarterly Report) U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exa |
|
| October 16, 2017 |
Note Payable to Magna Acquisition LLC dated September 5, 2017. (11) PROMISSORY NOTE $3,000.00 September 5, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Three Thousand Dollars (US$3,000), together |
|
| July 14, 2017 |
Note Payable to Magna Acquisition LLC dated April 28, 2017. (10) EX-10.53 6 e616381ex10-53.htm PROMISSORY NOTE $1,000.00 April 28, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of One Thousand Dol |
|
| July 14, 2017 |
Note Payable to Magna Acquisition LLC dated April 10, 2017. (10) EX-10.51 4 e616381ex10-51.htm PROMISSORY NOTE $5,000.00 April 10, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Five Thousand Do |
|
| July 14, 2017 |
Note Payable to Magna Acquisition LLC dated March 6, 2017.(10) PROMISSORY NOTE $2,500.00 March 6, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hundred Dollars (US2,500), together |
|
| July 14, 2017 |
Note Payable to Magna Acquisition LLC dated April 11, 2017. (10) EX-10.52 5 e616381ex10-52.htm PROMISSORY NOTE $1,000.00 April 11, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of One Thousand Dol |
|
| July 14, 2017 |
Note Payable to Magna Acquisition LLC dated March 7, 2017. (10) EX-10.50 3 e616381ex10-50.htm PROMISSORY NOTE $5,000.00 March 7, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Five Thousand Dol |
|
| July 14, 2017 |
Note Payable to Magna Acquisition LLC dated May 31, 2017. (10) EX-10.54 7 e616381ex10-54.htm PROMISSORY NOTE $7,500.00 May 31, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Seven Thousand Fiv |
|
| July 14, 2017 |
MAGAA / Magna-Lab, Inc. 10-Q (Quarterly Report) 10-Q 1 e61638110q-magna.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0- |
|
| July 14, 2017 |
Note Payable to Magna Acquisition LLC dated June 6, 2017. (10) EX-10.55 8 e616381ex10-55.htm PROMISSORY NOTE $5,500.00 June 6, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Five Thousand Five |
|
| June 14, 2017 |
MAGAA / Magna-Lab, Inc. 10-K (Annual Report) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended February 28, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Name of re |
|
| June 14, 2017 |
PROMISSORY NOTE $5,000.00 January 6, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Five Thousand Dollars (US5,000), together wit |
|
| June 14, 2017 |
PROMISSORY NOTE $2,500.00 December 15, 2016 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hundred Dollars (US2,500), toge |
|
| June 14, 2017 |
EX-10.42 2 e616278ex10-42.htm PROMISSORY NOTE $2,500.00 December 1, 2016 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hu |
|
| June 14, 2017 |
PROMISSORY NOTE $5,000.00 February 20, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Five Thousand Dollars (US5,000), together w |
|
| June 14, 2017 |
PROMISSORY NOTE $2,500.00 January 5, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hundred Dollars (US2,500), togeth |
|
| June 14, 2017 |
ASSET PURCHASE AGREEMENT THIS AGREEMENT dated as of December 14, 2016 between Lawrence A. |
|
| June 14, 2017 |
EX-10.46 6 e616278ex10-46.htm PROMISSORY NOTE $2,500.00 February 2, 2017 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Hu |
|
| May 30, 2017 |
Form 12b-25. - NOTIFICATION OF LATE FILING FORM 12b-25 SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR For Period Ended: February 28, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Trans |
|
| January 13, 2017 |
Unassociated Document U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-2 |
|
| October 12, 2016 |
Unassociated Document U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-213 |
|
| July 12, 2016 |
Unassociated Document PROMISSORY NOTE $25,000.00 June 7, 2016 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Five Thousand Doll |
|
| July 12, 2016 |
Unassociated Document U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 |
|
| June 10, 2016 |
Unassociated Document U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended February 29, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magn |
|
| May 31, 2016 |
NT 10-K 1 e615098nt10k-magna.htm Form 12b-25. - NOTIFICATION OF LATE FILING FORM 12b-25 SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR For Period Ended: February 29, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Trans |
|
| January 14, 2016 |
PROMISSORY NOTE $15,000 December 29, 2015 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc. |
|
| January 14, 2016 |
MAGAA / Magna-Lab, Inc. 10-Q - Quarterly Report - U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (E |
|
| January 11, 2016 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant Unassociated Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 11, 2016 |
Unassociated Document Exhibit 16.1 January 8, 2016 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated January 6, 2016 of Magna-Lab, Inc. and are in agreement with the statements with regards to the dismissal of Liggett, Vogt & Webb, P.A. in the first, second, third and fourth paragraphs therein in their entire |
|
| October 6, 2015 |
PROMISSORY NOTE $15,000.00 August 3, 2015 EX-10.39 3 e614167ex10-39.htm PROMISSORY NOTE $15,000.00 August 3, 2015 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (“Borrower”), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( “Lender”), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Fifteen Thousan |
|
| October 6, 2015 |
PROMISSORY NOTE $15,000.00 June 11, 2015 PROMISSORY NOTE $15,000.00 June 11, 2015 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (?Borrower?), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( ?Lender?), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Fifteen Thousand Dollars (US$15,000), together |
|
| October 6, 2015 |
10-Q 1 e61416710q-magna.htm U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number |
|
| July 9, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended: May 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exact na |
|
| June 24, 2015 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant Unassociated Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 24, 2015 |
Re: Magna-Lab, Inc. Commission File Number: 0-21320 Unassociated Document Exhibit 16.1 June 24, 2015 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549-7561 Re: Magna-Lab, Inc. Commission File Number: 0-21320 Dear Sir or Madam: We have read Item 4.01 of Form 8-K of Magna-Lab, Inc. dated June 24, 2015, and agree with the statements concerning our Firm contained therein. Sincerely, /s/ CITRIN |
|
| June 15, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended February 28, 2015 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Name of re |
|
| June 15, 2015 |
PROMISSORY NOTE $10,000.00 May 27, 2015 PROMISSORY NOTE $10,000.00 May 27, 2015 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (?Borrower?), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( ?Lender?), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Ten Thousand Dollars (US$10,000), together with |
|
| June 15, 2015 |
PROMISSORY NOTE $15,000.00 June 11, 2015 PROMISSORY NOTE $15,000.00 June 11, 2015 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (?Borrower?), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( ?Lender?), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Fifteen Thousand Dollars (US$15,000), together |
|
| May 29, 2015 |
Unassociated Document Form 12b-25. - NOTIFICATION OF LATE FILING FORM 12b-25 SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form N-SAR For Period Ended: February 28, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Repor |
|
| January 14, 2015 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: November 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (E |
|
| October 17, 2014 |
U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: August 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-21320 Magna-Lab Inc. (Exa |
|
| October 17, 2014 |
PROMISSORY NOTE $24,000.00 October 14, 2014 PROMISSORY NOTE $24,000.00 October 14, 2014 FOR VALUE RECEIVED, the undersigned, Magna-Lab Inc., a New York corporation (?Borrower?), HEREBY PROMISES TO PAY to the order of Magna Acquisition LLC or its registered assigns ( ?Lender?), in lawful money of the United States of America, in the manner and at the times provided hereinafter, the principal sum of Twenty Four Thousand Dollars (US$24,000), t |
|
| October 15, 2014 |
MAGAA / Magna-Lab, Inc. NT 10-Q - - NT 10-Q 1 e61277212b25-magna.htm Form 12b-25. - NOTIFICATION OF LATE FILING FORM 12b-25 SEC FILE NUMBER 0-21320 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Check One): oForm 10-K oForm 20-F oForm 11-K xForm 10-Q oForm N-SAR For Period Ended: August 31, 2014 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tran |
|
| July 3, 2014 |
June 30, 2014 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Re: Magna-Lab Inc. Commission File No. 0-21320 We have read the statements that we understand Magna-Lab, Inc. will include under Item 4.01 of the Form 8-K report it will file regarding the dismissal of its auditor. We agree with such statements made regarding our firm. We have |
|
| July 3, 2014 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 30, 2014 MAGNA-LAB, INC. (Exact name of Registrant as Specified in its Charter) New York 0-21320 11-3074326 (State or Other Jurisdiction of Incorporation) (Commission file Number) |
